58 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 ROUNDTABLE capacity, ensuring proximity to key markets and reducing reliance on distant supply routes. Second, we’re diversifying raw material sources and supplier networks to mitigate risk and improve continuity across both traditional and advanced therapies. Third, we’re engaging early with regulators so we’re prepared not just for today’s standards, but for tomorrow’s as well. By combining scale and resilience in small molecules with targeted investments in peptides and ADCs, Axplora is ensuring we are ready for the therapies of the future without compromising the medicines patients depend on today. What do you look for in a strategic partner at CPHI and beyond? PV. We look for partners who combine innovation with reliability. Key criteria include technological complementarity, a shared commitment to quality and sustainability and the agility to adapt to a fast-changing industry. Transparency, long-term engagement and a willingness to co-invest in new platforms or markets are crucial. At CPHI and beyond, we’re not only evaluating technologies, but also seeking cultural alignment and the ability to create real value together. ML. At Hongene, strategic partnerships are about more than transactions, they reflect a shared commitment to advancing transformative medicines. Our mission is to continuously innovate to make RNA medicines accessible and affordable for patients worldwide. We seek partners who value long-term collaboration and share our vision. Because we support programs from discovery to commercial launch, we value partners who recognise the benefit of simplifying supply chains, accelerating timelines and enhancing regulatory compliance through vertical integration. Innovation is at the core of our partnerships. We’re investing in next-generation technologies like chemoenzymatic ligation and structureguided mRNA designs to advance the future of nucleic acid development. Partners who share this forward-thinking mindset will find in Hongene a collaborator dedicated to enabling their science and delivering maximal impact for patients globally. BC. When we think about strategic partnerships, we look beyond transactional relationships. For Mabion, the ideal partner shares a long-term vision and is committed to collaboration throughout the product lifecycle. This means engaging early in development, aligning on regulatory strategy and working together to anticipate scale-up and commercialisation challenges. Trust and transparency are essential. We value partners who view us as an extension of their team and who are open about their needs, expectations and challenges. In return, we commit to the same level of openness. This foundation allows us to solve problems together and accelerate timelines without compromising quality. Another key factor is scientific and technical complementarity. We look for partners who bring innovative pipelines and modality expertise that align with our biologics development and manufacturing. By combining our strengths, we can create differentiated solutions that bring therapies to patients faster and more reliably. By working with like-minded companies, we not only advance science, but also build resilient, ethical, and sustainable supply chains. At CPHI and beyond, these shared values are what define true strategic partnerships for Mabion. MM. We value partnerships built on trust, shared innovation, and a long-term vision. The most successful collaborations happen when customers involve us early – from development through to commercial supply. That’s when we can co-develop solutions, accelerate timelines and design end-to-end strategies that truly meet patient needs. This year, we have announced over E100 million of investment across our sites. This is a prime example of how co-creation with customers leads to stronger outcomes. At CPHI, we want to connect with companies that share this mindset. We’re seeking partners who see value in collaboration, who are open to tackling complexity together, and who understand that speed and reliability are competitive advantages in today’s market. Above all, we’re looking for relationships where we can relentlessly focus on understanding customer needs because that’s where Axplora delivers its best work and where together we can bring life-changing medicines to patients faster. LS. We value customer partnerships that are rooted in transparency, shared goals, and a longterm view of success. At CPHI and beyond, we’re looking forward to meeting with our customers to discuss their desired outcomes and share our latest innovations and solutions to help them get there. We are always looking for customers who partner to grow with us, who see value in early engagement, co-innovation, and a relationship that evolves with the market.
RkJQdWJsaXNoZXIy MjY2OTA4MA==